Absorption, distribution, metabolism and excretion of daily oral doses of [14C]methyl parathion in hens

被引:21
|
作者
Abu-Qare, AW [1 ]
Abdel-Rahman, AA [1 ]
Ahmad, H [1 ]
Kishk, AM [1 ]
Abou-Donia, MB [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA
关键词
methyl parathion; p-nitrophenol; pharmacokinetics; hens; organophosphates;
D O I
10.1016/S0378-4274(01)00409-X
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Adult hens were given oral daily doses of 2 mg (2 muC(i))/kg/day (14% of oral LD50 in male rats) of [C-14]methyl parathion (O,O-dimethyl O-4-nitrophenyl phosphorothioate) for 10 consecutive days. Five treated hens were sacrificed at 1, 2, 4, 8, 12, 24, and 48 h after the last dose. Methyl parathion was absorbed from the gastrointestinal tract and distributed rapidly. Maximum radioactivity was detected in tissues within 8 h of dosing, (ng methyl parathion equivalent/g fresh tissue or ml plasma): Plasma (189.2), liver (94.7), kidney (146.2), brain (61.4), gastrointestinal tissues (106.7). Methyl parathion was detected in the plasma, kidney and liver, while methyl parathion metabolite p-nitrophenol was detected in the liver and in the kidney. Elimination of methyl parathion from plasma was monophasic with a terminal half-life of 17.5 h, corresponding to an elimination rate constant of 0.039 ng/hr. Most of the absorbed radioactivity was excreted in the combined fecal-urine excreta (98%). Analysis of the metabolites in the excreta revealed that non-conjugated metabolites accounted for 13% of the total excretion. Conjugated metabolites accounted for 87% of the total excretion; of that, 6% as p-nitrophenyl-glucoronide conjugate, 7% as p-nitrophenyl-sulfate conjugate, 23% as bound hot sulfric acid hydrolyzable residues, and 51% as water soluble metabolites. The presence of majority of radioactivity in the excreta as conjugated metabolites indicates that determining only unbound p-nitrophenol as a biological marker for methyl parathion exposure underestimates total fecal-urine excretion of p-nitrophenol. The slow elimination rate of methyl parathion is significant, since hens are more comparable to humans with respect to their cytochrome P450 activities. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [31] Metabolism and excretion of [14C]taranabant, a cannabinoid-1 inverse agonist, in humans
    Karanam, Bindhu
    Addy, Carol
    Bateman, Thomas
    Reddy, Vijay Bhasker
    Li, Susie
    Dean, Dennis
    Li, Hankun
    Jones, Allen
    Schenk, David
    Zhang, Andy Shiqiang
    Braun, Matt
    Freeman, Amanda
    Flach, Stephen
    Stoch, Aubrey
    Chodakewitz, Jeff
    Wagner, John A.
    Kumar, Sanjeev
    XENOBIOTICA, 2010, 40 (10) : 691 - 700
  • [32] A Phase I Study to Investigate the Absorption, Pharmacokinetics, and Excretion of [14C] Prucalopride After a Single Oral Dose in Healthy Volunteers
    Flach, Stephen
    Scarfe, Graeme
    Dragone, Jeffrey
    Ding, Jie
    Seymour, Mark
    Pennick, Mike
    Pankratz, Todd
    Troy, Steven
    Getsy, Jay
    CLINICAL THERAPEUTICS, 2016, 38 (09) : 2106 - 2115
  • [33] Absorption, metabolism and excretion of [14C]-sotorasib in healthy male subjects: characterization of metabolites and a minor albumin-sotorasib conjugate
    Irene Vuu
    Upendra P. Dahal
    Zhe Wang
    Xiaomeng Shen
    John Rodgers
    Jan Wahlstrom
    Brett Houk
    Cancer Chemotherapy and Pharmacology, 2022, 90 : 357 - 367
  • [34] Absorption, metabolism and excretion of [14C]-sotorasib in healthy male subjects: characterization of metabolites and a minor albumin-sotorasib conjugate
    Vuu, Irene
    Dahal, Upendra P.
    Wang, Zhe
    Shen, Xiaomeng
    Rodgers, John
    Wahlstrom, Jan
    Houk, Brett
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 90 (04) : 357 - 367
  • [35] Absorption, Metabolism and Excretion of [14C]Mirabegron (YM178), a Potent and Selective β3-Adrenoceptor Agonist, after Oral Administration to Healthy Male Volunteers
    Takusagawa, Shin
    van Lier, Jan Jaap
    Suzuki, Katsuhiro
    Nagata, Masanori
    Meijer, John
    Krauwinkel, Walter
    Schaddelee, Marloes
    Sekiguchi, Mitsuhiro
    Miyashita, Aiji
    Iwatsubo, Takafumi
    van Gelderen, Marcel
    Usui, Takashi
    DRUG METABOLISM AND DISPOSITION, 2012, 40 (04) : 815 - 824
  • [36] Excretion balance and pharmacokinetics following a single oral dose of [14C]-fedratinib in healthy subjects
    Ken Ogasawara
    Christine Xu
    Vanaja Kanamaluru
    Nicholas Siebers
    Sekhar Surapaneni
    Laurence Ridoux
    Maria Palmisano
    Gopal Krishna
    Cancer Chemotherapy and Pharmacology, 2020, 86 : 307 - 314
  • [37] Excretion balance and pharmacokinetics following a single oral dose of [14C]-fedratinib in healthy subjects
    Ogasawara, Ken
    Xu, Christine
    Kanamaluru, Vanaja
    Siebers, Nicholas
    Surapaneni, Sekhar
    Ridoux, Laurence
    Palmisano, Maria
    Krishna, Gopal
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (02) : 307 - 314
  • [38] Absorption, metabolism, and excretion of [14C]YY-20394, a highly selective PI3K-Delta inhibitor in humans
    Yu, Jinghua
    Zhang, Hua
    Zhang, Yifan
    Zhan, Yan
    Ma, Sheng
    Hu, Tao
    Zhang, Ning
    Lou, Yangtong
    Bao, Hanying
    Xu, Zusheng
    Zhong, Dafang
    Miao, Liyan
    Diao, Xingxing
    XENOBIOTICA, 2022, 52 (03) : 254 - 264
  • [39] Absorption, metabolism and excretion of C-14-candesartan and C-14-candesartan cilexetil in healthy volunteers
    vanLier, JJ
    vanHeiningen, PNM
    Sunzel, M
    JOURNAL OF HUMAN HYPERTENSION, 1997, 11 : S27 - S28
  • [40] Metabolism and disposition of [14C]tivantinib after oral administration to humans, dogs and rats
    Murai, Takahiro
    Takakusa, Hideo
    Nakai, Daisuke
    Kamiyama, Emi
    Taira, Tomoe
    Kimura, Tomoko
    Jimbo, Takeshi
    Bathala, Mohinder
    Pickersgill, Fraser
    Zahir, Hamim
    Tokui, Taro
    Savage, Ronald E.
    Ashwell, Mark A.
    Izumi, Takashi
    XENOBIOTICA, 2014, 44 (11) : 996 - 1008